Abstract:In the current antiretroviral landscape, continuous efforts are still needed to search for novel chemotypes of human immunodeficiency virus type 1 (HIV-1) inhibitors with improved drug resistance profiles and favorable drug-like properties. Herein, we report the design, synthesis, biological characterization, and druggability evaluation of a class of non-nucleoside reverse transcriptase inhibitors. Guided by the available crystallographic information, a series of novel indolylarylsulfone derivatives were rationally discovered via the substituent decorating strategy to fully explore the chemical space of the entrance channel. Among them, compound 11h bearing the cyano-substituted benzyl moiety proved to be the most effective inhibitor against HIV-1 wild-type and mutant strains (EC50 = 0.0039-0.338 μM), being far more potent than or comparable to etravirine and doravirine. Besides, 11h did not exhibit cytotoxicity at the maximum test concentration. Meanwhile, the binding target of 11h was further confirmed to be reverse transcriptase (IC50 = 0.055 μM). Preliminary structure-activity relationship were discussed to guide further optimization work. Molecular docking and dynamics simulation studies were investigated in detail to rationalize the biological evaluation results. Further drug-likeness assessment indicated that 11h possessed excellent physicochemical properties. Moreover, no apparent hERG blockade liability and cytochrome P450 inhibition were observed for 11h. Notably, 11h was characterized by favorable in vitro metabolic stability with moderate clearance rates and long half-lives in human plasma and liver microsomes. Overall, 11h holds great promise as an ideal Anti-HIV-1 lead compound due to its potent antiviral efficacy, low toxicity, and favorable drug-like profiles.

Discovery of Novel Dihydrothiopyrano[4,3- d ]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles

Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2- d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants

Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles

Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives As Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency Against Resistance-Associated Variants

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Identification of Dihydrofuro[3,4- D]pyrimidine Derivatives As Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives As HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.

Disubstituted pyrimidine-5-carboxamide derivatives as novel HIV-1 NNRTIs: Crystallographic overlay-based molecular design, synthesis, and biological evaluation

Discovery of Novel Diarylpyrimidines As Potent HIV-1 NNRTIs by Investigating the Chemical Space of a Less Explored "hydrophobic Channel"

Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach.

Discovery of Novel Diarylpyrimidine Derivatives As Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site

Design and Optimization of Piperidine-Substituted Thiophene[3,2-D]pyrimidine-based HIV-1 NNRTIs with Improved Drug Resistance and Pharmacokinetic Profiles

Discovery of Novel Fused-heterocycle-bearing Diarypyrimidine Derivatives As HIV-1 Potent NNRTIs Targeting Tolerant Region I for Enhanced Antiviral Activity and Resistance Profile

Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibito

Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles

Exploiting the Tolerant Region I of Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket (NNIBP): Discovery of Potent Diarylpyrimidine (DAPY)-typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.

Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles

Design, Synthesis, and Antiviral Evaluation of Novel Hydrazone‐substituted Thiophene[3,2‐d]pyrimidine Derivatives As Potent Human Immunodeficiency Virus‐1 Inhibitors

Exploring the Hydrophobic Channel of NNIBP Leads to the Discovery of Novel Piperidine-Substituted Thiophene[3,2-D]pyrimidine Derivatives As Potent HIV-1 NNRTIs

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Discovery of Thiophene[3,2-d]pyrimidine Derivatives As Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.